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The availability of a radioimmunoassay for prostate-specit ic acid phosphatase has allowed a corre!ative study between this technique and conventional colorimetric assays in the four clinical stages of prostatic adenocarcinoma. Results of such a study show an increased diagnostic sensitivity of the radioimmunoassay in all stages, but in 14% of Stage IV adenocarcinomas there was no increase in prostatic acid phosphatase above the ranges ordinarily expected for all methods. In cases of benign prostatic hyperplasia, there was an increase associated with in vivo tissue cytolysis, comparable to Stage II and Ill adenocarcinoma. The sensitivity of the test in Stage I is still low, but testing for combinations of tumor markers might increase the diagnostic yield. Conversely, a different clinical approach might be to establish baseline values in the "at-risk" patient, followed by regular determinations of prostate-specific acid phosphatase activity. Increases in activity within the normal expected range may be interpreted by the clinician as a herald of disease. ReceivedNov. 13, 1979; accepted Dec. 18, 1979. in fact, were challenged by Mahan and Doctor (9) . In the present study, therefore, I examined a large number of normal individuals, patients with the various clinical stages of prostatic adenocarcinoma, and patients with other neoplastic diseases, by using a sensitive and specific PSAP antibody in a radioimmunoassay technique.
The study is thus designed to elucidate the precise role of immunologically measured PSAP in diseases of the prostate gland. Reproducibility was determined by 20 consecutiveanalyses of 12 samples. The coefficient of variation ranged between 5 and 9% within-assay, and 7.5 to 10% between assays. The sensitivity of the method, defined as the concentration equivalent to twice the standard deviation of the zero binding, was 1.0 zg/L. disease. An age breakdown by decades showed no significant difference in immunoassay values among the age groups. Sixty normal women were examined and, although some serum samples showed antigenic activity with the PSAP antisera, in no case did the value exceed 2.5 g/L.
Materials and Methods

Laboratory
Studies of Patients
Blood was sampled from each patient at least 24 h after rectal examination (11) . Because PSAP is one of the most unstable of the enzymes commonly measured clinically, specific precautions are necessary to ensure stability. For both assays (activity and RIA) blood was collected in an evacuated tube, which was placed in crushed ice. Within 30-60 mm the sample was centrifuged at 4 #{176}C and serum was separated from the cells. In the aliquot for the rate-reaction assays, 10 ML of glacial acetic acid was added per milliliter of serum, and the sample was stored at 4 #{176}C. Generally, the activity was assayed within 4 h of blood sampling.
For radioimmunoassay, the serum was stored at -70 #{176}C without acetic acid. Assays were performed in a batch about twice weekly, the average storage time being 72 h. Stability studies over a 24-h period indicated antigenic activity was retained without loss at 4 #{176}C in nonacid-treated serum. Fresh serum stored at -70 #{176}C retained antigenic activity for at least three months, as has been described for the acid-stabilized serum used in colorimetric assays (12) . were calculated from the accumulated data in the manner described by Galen and Gambino (13) . The sensitivity data for each clinical stage of prostatic In one caseofStage IV disease, the radioimmunoassay value was within the normal range,but there was increasedPSAP activity, as determined with thymolphthalein and para-nitrophenol.
Staging of the Patients
Improper sample handling may have been responsible for this false negative by RIA. In two cases within the clinically normal group, RIA gave above-normal results exceeding 100 jig/L, but the colorimetric methods indicatednormal activity. In both cases,the subjects were hyperlipidemic,with cholesterol>5.0 g/L and triglycerides >8.0 g/L. This would suggest that hyperlipidemia affects the technical performance of the RIA test. Table 3 compares our diagnostic results with those of three previous authors.In Stages I,II,and III, there appears to be a wide variationin diagnosticresults, especiallycompared with the report of Foti et al. (8) , who used a similarRIA technique.Our data agree betterwith those of Chu (14) , who used a counter-currentimmunoelectrophoresis method, and Mahan (9) , who used RIA.
With a statistical analysisof the data I sought answers to two questions:
(a) Isthe RIA method significantly betterthan the colonmetric activity assays indetectingcanceratthe variousstages? The p-values from McNemar's test (15) for correlatedproportions (Table 4) is compelling evidence for the combined data and strong for each individual stage except Stage I, which is,unfortunately,of particularinterest. However, in view of the statistical significanceforStages II and IV, the lack of statistical significance forthe Stage Ia resultsappears to be due to insufficient sample size.
(b) Isthe RIA method effective fordetectingStage Icancer? It must be determined whether the true-positiverates for Stage I are (statistically) significantly higher than the falsepositiverateof 12/223 I found fornormal subjects. Using the standard testforthe differenceof independent proportions, I obtained the followingp-values:
Discussion
In the decisionto introducea new laboratory test or replace an olderone, severalcriteria must be evaluated.
Does the new testofferadvantages of specificity and sensitivity? The present data, in which an RIA-specific antibody technique is compared with common colorimetnicenzymic activity assays, show a definite improvement in sensitivity but a less significant change in specificity. Does the new test offer the advantage of reliability in repetitive testing? Experience over a six-month period suggests that there are few methodological false-positives or falsenegativeswith the test. A high concentrationof lipidscauses false-positives, and improper sample handling may account for falsenegatives.
Finally,does the testofferbetterdiagnosticaccuracy than other procedures used in investigating the same diseaseprocess-i.e., fewer falsepathophysiological positives? A few (9% by thisRIA) of those caseshistologically determined to have benign prostatic hyperplasiashowed enzyme activity thatwas above the normal range,which by tradition suggestsneoplasia. Most of these cases had eithermacro or micro areas of infarctionassociatedwith areas of cellularnecrosis,a finding thathad been previouslyreported by Howard and Fraley (16) . In 14 of the 19 cases,an indwellingurethralcatheterhad been in placeforat least72 h beforePSAP activity was determined. Nonetheless, the lingeringdoubt of a missed focus of tumor cellsremains and can be evaluated only by continued clinical and laboratoryobservations.
A broad varietyof other neoplasticdiseasesappear to re- showed an increase in the activity of PSAP by RIA. Several reasons may account for the differencein results. Clinically, the rigid staging procedure I applied is critical to the conclusions.Methodologically,although every precaution was taken to ensure enzyme stability, it is conceivable that thereare differences in specificity and sensitivity between the two antibodies used, because a more extensive purification procedure basis was used for the New England Nuclear antibody than for the FotL one. The resultsIpresent correspond closelyto those of Mahan and Doctor (9) and to those of Chu (14) . Only considerable further practicalexperience willanswer the question.
Whichever study one accepts,one cannot be euphoric over the positive diagnostic yield of 12%. The realistic question that must now be asked, in view of the accumulated data by a clearlyimproved methodological approach is:are we examiningthe rightbiochemical parameters?
Is it possible for any biochemical technique, even with superb specificity and sensitivity, to detect the enzyme output of a small focus of tumor cells in the prostate (or any other organ) after dilution in a 5-L blood pool, and at a pH foreign to that of its natural milieu? One must accept the limitations, both physiologicaland methodological.
There isslightevidence that an increasein the number of tumor markers examined in combination with PSAP, such as ribonuclease (14) , creatinekinase isoenzyme I (BB) (18) , and lactate dehydrogenase isoenzymes 4 and 5 (19) , may increase diagnosticsensitivity. Or there may be a differentclinical approach.
All the data in this study, as in past studies, have taken single-point analysisof enzyme activity, and deviation above the upper limitof normal in thisanalysis, as the index ofabnormality.For individuals"at risk"thismay be a serious errorinjudgment: a subtleincreasewithin the normal range may be more significant. For example, an individualmonitored over a period of apparent good health will show a consistentbaselinePSAP. Ifsamples taken under identicalcircumstances (20) to the baseline samples show increases that persist over time, yet remain within the normal range, such changes may have diagnostic significance. Perhaps we should consider the estimation of PSAP activity the male counterpart of the Papanicolaou smear, and apply a similar routine application in the defined "at-risk" population-i.e., American blacks from age 45, American whites at 50, and so on.
